What is a stock summary page? Click here for an overview.
Business Description
Kuros Biosciences Ltd
ISIN : CH0325814116
Description
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.74 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -3.2 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 17.53 | |||||
| Beneish M-Score | -2.17 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 69 | |||||
| 3-Year EBITDA Growth Rate | 54.7 | |||||
| 3-Year EPS without NRI Growth Rate | 24.2 | |||||
| 3-Year Book Growth Rate | -12.9 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.51 | |||||
| 9-Day RSI | 40.62 | |||||
| 14-Day RSI | 40.28 | |||||
| 3-1 Month Momentum % | 13.72 | |||||
| 6-1 Month Momentum % | 13.16 | |||||
| 12-1 Month Momentum % | 370.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.14 | |||||
| Quick Ratio | 1.69 | |||||
| Cash Ratio | 0.84 | |||||
| Days Inventory | 190.29 | |||||
| Days Sales Outstanding | 46.64 | |||||
| Days Payable | 99.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.9 | |||||
| Shareholder Yield % | -0.18 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.1 | |||||
| Operating Margin % | -6.61 | |||||
| Net Margin % | -4.92 | |||||
| FCF Margin % | 2.68 | |||||
| ROE % | -6.35 | |||||
| ROA % | -4.78 | |||||
| ROIC % | -9.44 | |||||
| 3-Year ROIIC % | -15.74 | |||||
| ROC (Joel Greenblatt) % | -42.51 | |||||
| ROCE % | -5.04 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.74 | |||||
| PB Ratio | 12.67 | |||||
| Price-to-Tangible-Book | 30.41 | |||||
| Price-to-Free-Cash-Flow | 370.6 | |||||
| Price-to-Operating-Cash-Flow | 239.54 | |||||
| EV-to-EBIT | -226.06 | |||||
| EV-to-EBITDA | -1288.25 | |||||
| EV-to-Revenue | 9.57 | |||||
| EV-to-FCF | 356.37 | |||||
| Price-to-GF-Value | 2.01 | |||||
| Price-to-Median-PS-Value | 0.7 | |||||
| Price-to-Net-Current-Asset-Value | 38.92 | |||||
| Earnings Yield (Greenblatt) % | -0.44 | |||||
| FCF Yield % | 0.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kuros Biosciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 75.555 | ||
| EPS (TTM) (CHF) | -0.103 | ||
| Beta | 0.71 | ||
| 3-Year Sharpe Ratio | 1.33 | ||
| 3-Year Sortino Ratio | 6.26 | ||
| Volatility % | 52.12 | ||
| 14-Day RSI | 40.28 | ||
| 14-Day ATR (CHF) | 0.87179 | ||
| 20-Day SMA (CHF) | 20.413461 | ||
| 12-1 Month Momentum % | 370.65 | ||
| 52-Week Range (CHF) | 5.07996 - 31.85 | ||
| Shares Outstanding (Mil) | 37.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kuros Biosciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kuros Biosciences Ltd Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kuros Biosciences Ltd Frequently Asked Questions
What is Kuros Biosciences Ltd(LTS:0RHR)'s stock price today?
The current price of LTS:0RHR is CHF19.46. The 52 week high of LTS:0RHR is CHF31.85 and 52 week low is CHF5.08.
When is next earnings date of Kuros Biosciences Ltd(LTS:0RHR)?
The next earnings date of Kuros Biosciences Ltd(LTS:0RHR) is .
Does Kuros Biosciences Ltd(LTS:0RHR) pay dividends? If so, how much?
Kuros Biosciences Ltd(LTS:0RHR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers